14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
KIDS vs IRMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas IRMD carries 44.9/100 (HOLD) at $81.26 (33.4x Forward P/E, 32.3% operating margin).
Technical & Structure Timing Caution: KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2); meanwhile IRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KIDS vs IRMD. Trailing 12-month operating profitability (KIDS -8.2% vs IRMD 32.3%) and valuation multiples (KIDS N/M vs IRMD 33.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment82.0% of Rev ($217M)
90D Engineering Disclosures0 Published
IRMD Moat ProfileHigh-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $1.0B market capitalization and 32.3% operating margin.
OpEx & R&D Reinvestment43.2% of Rev ($39M)
90D Engineering Disclosures0 Published
Investor FAQ KIDS vs IRMD Key Questions & Quantitative Answers
As of Nov 19, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas IRMD carries 44.9/100 (HOLD) at $81.26 (33.4x Forward P/E, 32.3% operating margin). Technical & Structure Timing Caution: KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2); meanwhile IRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KIDS leads the Growth & Scale pillar: KIDS posts +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin), compared with IRMD at +14.2% YoY revenue growth and +18.3% YoY earnings growth on $89M TTM revenue (75.5% gross margin, 32.3% operating margin). On trailing 12-month operating scale, KIDS generates $264M in USD-normalized revenue versus $89M for IRMD. In operating R&D and SG&A reinvestment, KIDS deploys 82.0% of Rev ($217M) (0 90-day corporate R&D disclosures) versus 43.2% of Rev ($39M) (0 disclosures) for IRMD.
IRMD screens cheaper on headline valuation multiples. KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin), whereas IRMD trades at 33.4x Forward P/E, 43.9x Trailing P/E, 4.46x PEG, and 11.7x EV/Revenue (28.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KIDS (-9.8% ROE) versus IRMD (23.4% ROE) capital efficiency.
In options market volatility and institutional positioning, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk). By comparison, IRMD carries 33.6% implied volatility (4th %ile, Compressed (<25th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.74β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.